Skip to main content
Caplight Logo









Ocuvex Therapeutics, Inc.

Ocuvex Therapeutics, Inc.

Private
New Hyde Park, New YorkHealthcare & Life Scienceshttps://ocuvextherapeutics.com/

Last Round

M&A

Aug 19, 2024

Total Funding Raised

$7M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Ocuvex Therapeutics, Inc. is a biopharmaceutical company that focuses on the development and commercialization of ophthalmic therapeutic candidates for the treatment of glaucoma and other ocular diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalophthalmic therapeuticseye caredrug discoveryclinical-stageophthalmologydrug developmentbiotechclinical trialsophthalmic diseasespharmaceutical pipelineeye disease managementpharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ocuvex Therapeutics, Inc. Comparables

Compare Ocuvex Therapeutics, Inc. with similar companies based on industry and business-model similarity.

Ocuvex Therapeutics, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ONL Therapeutics
81%
Qlaris Bio
81%
Galimedix Therapeutics
80%

Ocuvex Therapeutics, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AAug 19, 2024
SeedAug 3, 2022

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 101% MoM, reaching 2.8K.

  • Jul 25, 2026

    Monthly visitors grew 108% MoM, reaching 1.4K.

Ocuvex Therapeutics, Inc. Filings

Explore SEC and related filing metadata, where available.

Ocuvex Therapeutics, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Ocuvex Therapeutics, Inc.'s valuation, stock price, and market status.

Is Ocuvex Therapeutics, Inc. a public or private company?

Ocuvex Therapeutics, Inc. is a private company.

What is the current stock price of Ocuvex Therapeutics, Inc.?

Ocuvex Therapeutics, Inc. is a private company with no public stock price. Caplight tracks Ocuvex Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Ocuvex Therapeutics, Inc. worth (valuation)?

Valuation information for Ocuvex Therapeutics, Inc. is not publicly available.

Can I buy Ocuvex Therapeutics, Inc. stock?

Ocuvex Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Ocuvex Therapeutics, Inc.'s last funding round?

Ocuvex Therapeutics, Inc.'s most recent funding round was M&A on August 19, 2024.

Who are the main investors in Ocuvex Therapeutics, Inc.?

Investor information for Ocuvex Therapeutics, Inc. is not publicly disclosed.

Will Ocuvex Therapeutics, Inc. IPO soon?

No public IPO plans have been announced for Ocuvex Therapeutics, Inc..

How can I track Ocuvex Therapeutics, Inc. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ocuvex Therapeutics, Inc.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew Hyde Park, New York
Employee Range2
Year Founded2024
Last FundingAug 19, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?